$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
FDA approves lorlatinib for first-line treatment of ALK-positive metastatic lung cancer_Canghule
2025-10-19 11:44:20
Check Details
Rybrevant Instructions, Rybrevant Indications, Usage and Dosage
2025-10-19 11:44:20
Check Details
Has Rybrevant, a targeted therapy for mutant lung cancer, been approved by the FDA?
2025-10-19 11:44:20
Check Details
What is the effect of Rybrevant, the first targeted therapy for difficult-to-treat lung cancer?
2025-10-19 11:44:20
Check Details
Rybrevant targeted drug, the latest lung cancer drug approved for marketing?
2025-10-19 11:44:20
Check Details
When will Lumakras (sotorasib) be available in China? What disease is treated?
2025-10-19 11:44:20
Check Details
What kind of people are suitable for using Lumakras? What are the precautions for using Lumakras
2025-10-19 11:44:20
Check Details
[News Flash] Lumakras, the first KRAS-targeting drug for lung cancer, is approved by the FDA for marketing
2025-10-19 11:44:20
Check Details
How much does a box of Lumakras cost in 2021? Where can I buy imported Lumakras cheaper?
2025-10-19 11:44:20
Check Details
How long does it take for resistance to icotinib to develop? What are the symptoms of icotinib resistance?
2025-10-19 11:44:20
Check Details
How much does a box of the new lung cancer drug Icotinib cost? Can the targeted drug icotinib be purchased in domestic pharmacies?
2025-10-19 11:44:20
Check Details
Nivolumab/ipilimumab combination chemotherapy can treat advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
10017
10018
10019
10020
10021
10022
10023
...
10234
10235
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lyrfigtu (lirafugratinib) for Pretreated FGFR2 Cholangiocarcinoma: 70mg Daily, REFOCUS Efficacy, Ocular and Phosphate Monitoring
2
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
3
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
4
Elagolix GnRH Antagonist for Endometriosis Pain: Mechanism, Dosing, Bone and Mood Safety
5
Diazoxide Oral Suspension Inadequate Response: Glucose-Based Titration, Stop at 2–3 Weeks, Re-evaluate Hypoglycemia Cause
6
Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Lemborexant for Insomnia: Dual Orexin 5/10mg, 7-Hour Bedtime, 7–10-Day Review and Safety
10
Fayuvi (rebisufligene etisparvovec-hopf) for MPS IIIA: AAV9 Single Infusion, Weight-Based Dose, Steroids, Liver/Platelet Monitoring
11
Trelagliptin Once-Weekly DPP-4 for Type 2 Diabetes: Dosing, Renal Adjustment, Discontinuation
12
Orforglipron (Foundayo) vs Metformin: Oral GLP-1 Weight Loss and T2D Use